Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Screening, Diagnosis, and Treatment

Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Screening, Diagnosis, and Treatment

Nonalcoholic fatty liver disease (NAFLD), recently renamed metabolic dysfunction-associated steatotic liver disease (MASLD) affects ~70% of patients with type 2 diabetes (T2D), with ~20% showing signs of advanced liver fibrosis. Patients with T2D are at an increased risk of developing cirrhosis, liv...

Full description

Bibliographic Details
Main Authors:	Stefano Ciardullo, Michela Vergani, Gianluca Perseghin
Format:	Article
Language:	English
Published:	MDPI AG 2023-08-01
Series:	Journal of Clinical Medicine
Subjects:	NAFLD MASLD GLP1-RA SGLT2-I fibrosis screening
Online Access:	https://www.mdpi.com/2077-0383/12/17/5597

Similar Items

Nonalcoholic Fatty Liver Disease, Liver Fibrosis and Cardiovascular Disease in the Adult US Population
by: Stefano Ciardullo, et al.
Published: (2021-07-01)

Efficacy of Glucagon-Like Peptide-1 Analogs in Nonalcoholic Fatty Liver Disease: A Systematic Review
by: Teshome G, et al.
Published: (2020-09-01)

From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials
by: Ming-Lun Yeh, et al.
Published: (2023-10-01)

Aerobic and Muscle-Strengthening Physical Activity, Television Viewing, and Nonalcoholic Fatty Liver Disease: The CARDIA Study
by: Daniel J. McDonough, et al.
Published: (2023-08-01)

Nonalcoholic steatohepatitis: A comprehensive updated review of risk factors, symptoms, and treatment
by: Feryal Savari, et al.
Published: (2024-04-01)

Exploring the Multifaceted Landscape of MASLD: A Comprehensive Synthesis of Recent Studies, from Pathophysiology to Organoids and Beyond
by: Allison Soto, et al.
Published: (2024-02-01)

Semaglutide in the treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
by: Magdalena Mazurek, et al.
Published: (2023-02-01)

Cross talk between the liver microbiome and epigenome in patients with metabolic dysfunction-associated steatotic liver diseaseResearch in context
by: Carlos Jose Pirola, et al.
Published: (2024-03-01)

A gut microbiome signature for HIV and metabolic dysfunction-associated steatotic liver disease
by: Javier Martínez-Sanz, et al.
Published: (2023-12-01)

Glucagon-like Peptide-1 Receptor Agonists—A Potential New Medication for Pediatric Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD)
by: Erika Choi, et al.
Published: (2024-02-01)

The Effect Of SGLT-2 Inhibitors On Improving Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis.
by: Wasef Sayeh, et al.
Published: (2023-12-01)

Vibration-Controlled Transient Elastography and Controlled Attenuation Parameter for the Diagnosis of Liver Steatosis and Fibrosis in Patients with Nonalcoholic Fatty Liver Disease
by: Sebastian Zenovia, et al.
Published: (2021-04-01)

The Role of GLP1-RAs in Direct Modulation of Lipid Metabolism in Hepatic Tissue as Determined Using In Vitro Models of NAFLD
by: Ana Petrovic, et al.
Published: (2023-05-01)

Comparative effects between old and new antidiabetic agents on metabolic- associated fatty liver disease (MAFLD)
by: André J. Scheen
Published: (2023-07-01)

Does Therapy with Glucagon-like Peptide 1 Receptor Agonists Have an Effect on Biochemical Markers of Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD)? Pleiotropic Metabolic Effect of Novel Antidiabetic Drugs in Patients with Diabetes—Interventional Study
by: Marcin Hachuła, et al.
Published: (2023-08-01)

Associating Appendicitis with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Novel Insight into an Unexpected Connection
by: Christoph Roderburg, et al.
Published: (2024-02-01)

Prevalence of liver fibrosis in an unselected general population with high prevalence of obesity and diabetes mellitus. Time for screening?
by: Diego García-Compeán, et al.
Published: (2020-05-01)

Noninvasive assessment of nonalcoholic fatty liver disease
by: Gajanan A Rodge, et al.
Published: (2021-01-01)

The effects of Fc fusion protein glucagon-like peptide-1 and glucagon dual receptor agonist with different receptor selectivity in vivo studies
by: Peng Jiang, et al.
Published: (2024-05-01)

Protective effect of SGL5213, a potent intestinal sodium–glucose cotransporter 1 inhibitor, in nonalcoholic fatty liver disease in mice
by: Yasushi Honda, et al.
Published: (2021-10-01)

Role of mast cells in the pathogenesis of liver fibrosis in nonalcoholic fatty liver disease
by: Ewa Lewandowska, et al.
Published: (2020-05-01)

Efficacy of Off-Label Therapy for Non-alcoholic Fatty Liver Disease in Improving Non-invasive and Invasive Biomarkers: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
by: Qian Luo, et al.
Published: (2022-02-01)

Incident cardiac arrhythmias associated with metabolic dysfunction-associated steatotic liver disease: a nationwide histology cohort study
by: Tracey G. Simon, et al.
Published: (2023-12-01)

Role of Perturbated Hemostasis in MASLD and Its Correlation with Adipokines
by: Salvatore Pezzino, et al.
Published: (2024-01-01)

From MASH to HCC: the role of Gas6/TAM receptors
by: Daria Apostolo, et al.
Published: (2024-01-01)

Exploring Opportunities to Enhance the Screening and Surveillance of Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease (NAFLD) through Risk Stratification Algorithms Incorporating Ultrasound Elastography
by: Madalina-Gabriela Taru, et al.
Published: (2023-08-01)

Hepatic Stellate Cells: Dictating Outcome in Nonalcoholic Fatty Liver DiseaseSummary
by: Leke Wiering, et al.
Published: (2023-01-01)

Relationship between Dietary Fatty Acid Intake with Nonalcoholic Fatty Liver Disease and Liver Fibrosis in People with HIV
by: Cristiane Fonseca de Almeida, et al.
Published: (2021-09-01)

Nonalcoholic Fatty Liver Disease Progresses into Severe NASH when Physiological Mechanisms of Tissue Homeostasis Collapse
by: Silvia Sookoian, et al.
Published: (2018-03-01)

Gene Variants Implicated in Steatotic Liver Disease: Opportunities for Diagnostics and Therapeutics
by: Gary Huang, et al.
Published: (2023-10-01)

Exenatide ameliorates hepatic steatosis and attenuates fat mass and FTO gene expression through PI3K signaling pathway in nonalcoholic fatty liver disease
by: Shan Li, et al.
Published: (2018-06-01)

The Determinants of Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
by: Chia-Yen Dai, et al.
Published: (2022-06-01)

Saturated Fat-Mediated Upregulation of IL-32 and CCL20 in Hepatocytes Contributes to Higher Expression of These Fibrosis-Driving Molecules in MASLD
by: Katharina Schilcher, et al.
Published: (2023-08-01)

The Impact of Novel Anti-Diabetic Medications on CV Outcomes: A New Therapeutic Horizon for Diabetic and Non-Diabetic Cardiac Patients
by: Israel Mazin, et al.
Published: (2022-03-01)

Transcriptomics of MASLD Pathobiology in African American Patients in the Washington DC Area <sup>†</sup>
by: Tanmoy Mondal, et al.
Published: (2023-11-01)

Call to action: Understanding the differences in the use of SGLT-2 inhibitors and GLP-1 receptor agonists
by: Apurva Khedagi, et al.
Published: (2023-03-01)

Weight changes following antidiabetic mediation use: Real‐world evidence from health system data
by: Beini Lyu, et al.
Published: (2022-10-01)

Comparison between NAFLD fibrosis score and retinoic acid serum level in NAFLD
by: Ahmed Samir Allam, et al.
Published: (2020-01-01)

Environment, Endocrine Disruptors, and Fatty Liver Disease Associated with Metabolic Dysfunction (MASLD)
by: Antonella Mosca, et al.
Published: (2024-01-01)

Liver Stiffness, Albuminuria and Chronic Kidney Disease in Patients with NAFLD: A Systematic Review and Meta-Analysis
by: Stefano Ciardullo, et al.
Published: (2022-01-01)